89bio inc ETNB.US 總覽分析

美股醫療保健
(ETNB 無簡報檔)

ETNB 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位

ETNB 近期報酬表現

7.38%

89bio inc

3.56%

同產業平均

1.47%

S&P500

與 ETNB 同產業的標的表現

  • RAPP Rapport therapeutics inc
    價值 -趨勢 3 分波段 5 分籌碼 2 分股利 1 分
    查看更多

ETNB 公司資訊

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company's lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.

ETNB 股價